Genzyme GENZ
-
VHT Vanguard Health Care ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… Industries' TEVA acquisition of German generic drugmaker Ratiopharm Group International, Sanofi-Aventis' SNY acquisition of Genzyme , Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain drugmaker King Pharmaceuticals …
-
New Morningstar Analyst Report - Shire PLC
… Shire was also able to capitalize on Genzyme 's (now part of Sanofi SNY) manufacturing ..... international markets. However, Genzyme 's eventual recovery will weigh ..... the closing window to capitalize on Genzyme 's drug shortages prevent us from …
-
FDA Recommendations Bode Well For Pfizer
… directly at Sanofi ( SNY ) and their medication Imiglucerase. Sanofi inherited Imiglucerase in their recent acquisition of Genzyme . Even with severe production limitations Imiglucerase had over $ 550 million in sales Complete Story »
-
IXJ iShares S&P Global Healthcare ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… Industries' TEVA acquisition of German generic drugmaker Ratiopharm Group International, Sanofi-Aventis' SNY acquisition of Genzyme , Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain-drug maker King Pharmaceuticals …
-
RXL ProShares Ultra Health Care ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… Industries' TEVA acquisition of German generic drugmaker Ratiopharm Group International, Sanofi-Aventis' SNY acquisition of Genzyme , Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain-drug maker King Pharmaceuticals …
-
Why Billionaire Carl Icahn Could Target This Substantially Undervalued Biotech
… the board of Forest Laboratories ( FRX ), but this let down pales in comparison to his success at Biogen ( BIIB ) and Genzyme . Eli Lilly ( LLY ) is substantially undervalued and appears to many investors as a sinking ship. Moments like these are …
-
Sanofi: Healthy Dividend Yield But Little Upside In This Pharma Stock
… over $100 billion. The strong performance was driven by Genzyme , its growth platforms, and cost savings. The quarter also reflected the production recovery of Genzyme with the first shipment of Fabrazyme produced in Framingham …
-
Sanofi Posts Strong First Quarter as Cost-Cutting Helps Buoy the Bottom Line
… year period, which was expected, as the addition of Genzyme products and strong growth from diabetes drug Lantus helped ..... remainder of the year will see revenue declines as the Genzyme acquisition annualizes and generic competition continues …
-
Protalix With Higher Chances To Get Approved After Shire's News
… regarding production of VPRIV drug substance produced at their Lexington facility. Shire's Vpriv is the second after Genzyme ( SNY ) to reach the market for Gaucher disease, and an important potential competitor to Protalix's ( PLX ) taligucerase …
-
QQQ PowerShares QQQ ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… research and development programs. Recent mergers and acquisitions in this space include Sanofi-Aventis' SNY purchase of Genzyme and Merck of Germany's takeover of Millipore. Some quality biotech firms included in the 20 largest constituents of …